P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sa...(nation of pricing and product mix isexpe...),Health

Date:10/29/2008

nation of pricing and product mix is expected to impact sales growth by a positive two to three percent. Foreign exchange is expected to have a negative impact of one to two percent. The net impact of acquisitions and divestitures is estimated to lower net sales by one to two percent. Total sales are expected to increase one to three percent. This is a decrease of four percent versus the company's previous guidance range due to foreign exchange.

The Company also widened its earnings per share outlook range to $4.15 to $4.25. This maintains the high end of the Company's previous outlook, but recognizes the continued volatility in commodity and energy markets and increasing volatile foreign exchange markets. The company's outlook includes an estimated $0.50 per share of gain from the Folgers transaction and about $0.12 per share of incremental restructuring charges. Operating margin and tax rate guidance was unchanged.

For the October - December quarter, organic sales are expected to grow four to six percent. The combination of pricing and product mix is expected to contribute about four percent to sales growth. Foreign exchange is expected to have a negative impact of two to three percent. The net impact of acquisitions and divestitures is estimated to have a negative two percent impact on sales growth. Total sales are expected to be negative one to positive two percent.

The Company expects earnings per share to be in the range of $1.45 to $1.50 for the quarter, including the estimated $0.50 per share of Folgers gain and $0.03 per share of additional Folgers-related restructuring charges. Operating margin is expected to decline modestly as overhead productivity improvements will be more than offset by lower gross margins.

Forward Looking Statements

All statements, other than statements of historical fact included in this release, are forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act
'/>"/>

SOURCE The Procter & Gamble Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80